Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Date:10/13/2008

ary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION(R) Coronary Stent System. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery.

Long-term results with XIENCE V in the SPIRIT III pivotal U.S. clinical trial demonstrated a 45 percent reduction in the risk of MACE compared to TAXUS at two years. XIENCE V demonstrated a 32 percent reduction in TVF compared to TAXUS at two years. XIENCE V also demonstrated a low rate of stent thrombosis between one and two years, defined as very late stent thrombosis, per ARC definition of definite/probable stent thrombosis (0.3 percent for XIENCE V and 1.0 percent for TAXUS). XIENCE V met its primary endpoint in the SPIRIT III clinical trial with a statistically significant 50 percent reduction in in-segment late loss (vessel renarrowing) at eight months compared to TAXUS.

The XIENCE V stent is available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

XIENCE V was approved by the U.S. Food and Drug Administration and launched in July 2008, and was launched in Europe and other international markets in October 2006. XIENCE V is an investigational device in Japan and is currently under review by the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and s
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Ind. , Sept. 16, 2014   Evana ... of custom, automated assembly and test systems, recently received ... a leading medical device manufacturer. The Evana solution will ... quality and ergonomics, as well as reduce labor. ... automatically fed to Evana,s robotic assembly cell. The robot ...
(Date:9/16/2014)... , Sept. 16, 2014   Vestagen Technical Textiles, ... patient experience at hospitals. The myComfort™ line of patient ... barrier fabric that is fluid repellant, breathable and in ... the growth of bacteria on the fabric i . ... plays in the chain of transmission. We want myComfort ...
(Date:9/16/2014)... , Sept. 16, 2014  Synereca Pharmaceutics, ... novel orally active drugs that restore or ... today a $1.4 million convertible debt financing. ... life sciences accelerator Accele Biopharma, Inc., led ... a nationally recognized private not-for-profit corporation focused ...
Breaking Medicine Technology:Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... LEIDEN, The Netherlands, July 6 Three ... Therapeutics and InteRNA,Technologies - have joined public-private partnership TI ... on cancer and,inflammatory diseases, have a total budget of ... The new consortium, formed by Syncom, Synvolux Therapeutics, and,University ...
... , NEW YORK, June 30 Betsy McCaughey of the Committee ... hospital infection rates made available by the NYS Department of Health ... have the lowest infection rates - and steer clear of those ... , Betsy McCaughey, a Ph.D., founded RID in 2004 with a ...
Cached Medicine Technology:New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 2
(Date:9/16/2014)... September 16, 2014 Today, Top 10 ... the most recommended suppliers for the webmasters for people ... save money at the same time. , As an ... ) has been offering useful products at low prices ... connected to multiple GB connections to ensure that there ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Recently, the ... compared a lot of SEO hosting suppliers and announced ... most recommended suppliers for webmasters from the USA, UK, ... products (including VPS and cloud hosting) without spending a ... easy to use shared SEO hosting plans come with ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Care ... Logistics™, a component of the Hospital Operating System™ ... match patient needs with staff capacity. For the ... understanding of actual nursing and other staff capacity. ... of patient-care needs, anticipated admissions, discharges and transfers, ...
(Date:9/16/2014)... Randy Dotinga HealthDay Reporter , ... pattern baldness may face a higher risk of developing an ... a new study suggests. But, the study authors noted ... pattern of baldness should be concerned. Their study only found ... It did not prove cause and effect. "It is ...
(Date:9/16/2014)... September 15, 2014 Combining a standard chemotherapy ... from dividing improves both the survival and response ... new study by UT Southwestern Medical Center cancer ... the chemotherapy drug cisplatin with pemetrexed - an ... showed promising results for advanced, persistent, or recurrent ...
Breaking Medicine News(10 mins):Health News:Top 10 Best SEO Hosting: These Companies Are The Best Cheap SEO Hosting Suppliers In 2014 2Health News:Great SEO Hosting Suppliers Announced By Top 10 Best SEO Hosting 2Health News:Care Logistics Launches Demand Logistics as Part of the Hospital Operating System 2Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 2Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 3Health News:Cancer-fighting cocktail demonstrates promising results as treatment for advanced cervical cancer 2
... different types of dementia, but these findings are shocking. We ... study", say researchers Elisabet Englund and Hans Brunnstrm at Lund ... from the cities of Lund and Malm. All of them ... period 1996-2006 and been diagnosed with some form of dementia. ...
... Boston and Google.org have found web-based search data to be ... of outbreaks of dengue, an emerging mosquito-borne virus found in ... capture of disease-related queries in near real time, it could ... affected by dengue respond more quickly to nascent epidemics. ...
... new test that identifies the specific type of tumour they ... at the University of Edinburgh hope this improved diagnosis will ... the most effective drugs. The Edinburgh team worked with ... each of which had a different genetic signature. ...
... Private health clinics across Canada providing weight-loss surgeries are ... and at the expense of quality patient care, according to ... Chaim Bell. "The private clinics in Canada offer ... banding the upper stomach to restrict food intake to patients ...
... Randy Dotinga HealthDay Reporter , MONDAY, May 30 ... are marketed heavily toward children and teens, a leading association ... kids. Young children and teens should avoid energy drinks ... issued Monday, and routine consumption of sports drinks should be ...
... Ill. Functional magnetic resonance imaging (fMRI) may provide ... researchers at Columbia University in New York City, who ... children. Results of their study appear online and in ... is a spectrum disorder characterized by repetitive behaviors and ...
Cached Medicine News:Health News:Difficulties in diagnosing dementia type 2Health News:Searching the web for dengue 2Health News:Targeted testing offers treatment hope for ovarian cancer patients 2Health News:Private weight-loss surgery clinics shedding quality patient care 2Health News:Pediatricians Group Raps Energy and Sports Drinks for Kids 2Health News:Pediatricians Group Raps Energy and Sports Drinks for Kids 3Health News:New research may lead to improved diagnosis of autism 2
... Self-Cath Closed System is a latex-free ... for safe, simple catheterization designed to ... infections. It includes a 100% ... new EasyOff tear tab makes it ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... Closed System is a latex-free unisex ... safe, simple catheterization designed to reduce ... It includes a 100% latex-free ... EasyOff tear tab makes it easy ...
... System is a latex-free unisex system ... simple catheterization designed to reduce the ... It includes a 100% latex-free Mentor ... tear tab makes it easy to ...
Medicine Products: